Literature DB >> 21989449

Mesenchymal chondrosarcoma of the spleen: report of a case.

Anna Rossetto1, Enrico Saccomano, Aron Zompicchiatti, Claudio Avellini, Silvia Toffoli, GianMaria Miolo, Sergio Frustaci, Alessandro Uzzau.   

Abstract

BACKGROUND: Chondrosarcoma is a malignant tumor of chondrogenic origin and the mesenchymal type is a very rare finding. Mesenchymal chondrosarcoma tends to develop mostly in the skeleton but may also occur as a primary tumor in periosteal nervous and muscular tissues, the anterior cerebral falx, meninges, brain, maxillary sinus, eyelid, thyroid, pleura and mediastinum, while in the abdomen the most frequent locations are the kidney, retroperitoneum and even the perineum and the anogenital area. Apparently, the only splenic mesenchymal chondrosarcoma in the literature occurred in a dog. METHODS AND STUDY
DESIGN: Our paper reports the case of a patient who had a diagnosis of mesenchymal chondrosarcoma of the spleen. Results. We adopted surgery as the main therapeutic procedure without achieving complete recovery but preserving a good quality of life for our patient, minimizing the repercussions of the disease on her working and relational life.
CONCLUSIONS: The absence of important or invalidating symptoms and the persistence of good general conditions before and after each surgical operation encouraged us to adopt the surgical option as the most rational.

Entities:  

Mesh:

Year:  2011        PMID: 21989449     DOI: 10.1177/030089161109700423

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  3 in total

1.  Mesenchymal chondrosarcoma: a case report.

Authors:  Dang Vu Nguyen; Ahmad Sobri Muda; Yazmin Yaacob
Journal:  Malays J Med Sci       Date:  2013-05

2.  Mesenchymal chondrosarcoma metastasising to the pancreas.

Authors:  Christoph Paasch; Gianluca De Santo; Katherina Renate Boettge; Martin W Strik
Journal:  BMJ Case Rep       Date:  2018-12-31

Review 3.  Mesenchymal chondrosarcoma of bone and soft tissue: a systematic review of 107 patients in the past 20 years.

Authors:  Jie Xu; Dasen Li; Lu Xie; Shun Tang; Wei Guo
Journal:  PLoS One       Date:  2015-04-07       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.